Zacks Research Analysts Boost Earnings Estimates for Amarin Co. plc (NASDAQ:AMRN)

Amarin Co. plc (NASDAQ:AMRN) – Zacks Research raised their FY2025 earnings per share (EPS) estimates for Amarin in a research note issued on Tuesday, October 1st. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn ($0.19) per share for the year, up from their previous estimate of ($0.20). The consensus estimate for Amarin’s current full-year earnings is ($0.18) per share.

A number of other equities analysts have also weighed in on AMRN. Cantor Fitzgerald reiterated an “overweight” rating on shares of Amarin in a research report on Tuesday, June 18th. StockNews.com downgraded Amarin from a “buy” rating to a “hold” rating in a research note on Thursday, July 4th.

Amarin Stock Up 2.1 %

Shares of AMRN stock opened at $0.61 on Friday. Amarin has a fifty-two week low of $0.57 and a fifty-two week high of $1.37. The stock has a market capitalization of $248.79 million, a P/E ratio of -5.05 and a beta of 1.92. The stock has a 50-day simple moving average of $0.62 and a 200 day simple moving average of $0.76.

Institutional Investors Weigh In On Amarin

A number of institutional investors and hedge funds have recently made changes to their positions in AMRN. Arkfeld Wealth Strategies L.L.C. acquired a new stake in shares of Amarin during the second quarter worth $28,000. Significant Wealth Partners LLC raised its holdings in Amarin by 128.7% during the first quarter. Significant Wealth Partners LLC now owns 34,582 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 19,461 shares in the last quarter. Algert Global LLC bought a new stake in Amarin during the second quarter worth about $34,000. Prospect Financial Services LLC bought a new stake in Amarin during the second quarter worth about $41,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in Amarin by 66.3% in the first quarter. China Universal Asset Management Co. Ltd. now owns 74,178 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 29,579 shares during the period. Institutional investors own 22.25% of the company’s stock.

Insider Transactions at Amarin

In related news, CEO Aaron Berg bought 160,000 shares of the business’s stock in a transaction that occurred on Friday, August 2nd. The stock was acquired at an average price of $0.64 per share, for a total transaction of $102,400.00. Following the transaction, the chief executive officer now directly owns 805,380 shares of the company’s stock, valued at $515,443.20. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.96% of the stock is owned by insiders.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.